Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vaccitech plc (VACC)

2.37   0.03 (1.28%) 11-28 15:59
Open: 2.34 Pre. Close: 2.34
High: 2.4771 Low: 2.31
Volume: 9,315 Market Cap: 88(M)

Technical analysis

as of: 2022-11-28 4:43:59 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.05     One year: 3.44
Support: Support1: 2.07    Support2: 1.73
Resistance: Resistance1: 2.61    Resistance2: 2.94
Pivot: 2.37
Moving Average: MA(5): 2.36     MA(20): 2.46
MA(100): 3.61     MA(250): 5.54
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 43.1     %D(3): 38.3
RSI: RSI(14): 40.6
52-week: High: 12.71  Low: 2.07
Average Vol(K): 3-Month: 38 (K)  10-Days: 43 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VACC ] has closed above bottom band by 49.2%. Bollinger Bands are 59.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.48 - 2.49 2.49 - 2.5
Low: 2.28 - 2.3 2.3 - 2.31
Close: 2.35 - 2.37 2.37 - 2.39

Company Description

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Headline News

Mon, 28 Nov 2022
Snow and slippery roads ahead: Plan if you have medical needs - Public Health Insider

Mon, 28 Nov 2022
New Public Health recommendations make a syphilis test routine for women 45 and under - Public Health Insider

Mon, 28 Nov 2022
New VACC, TACC board elected - GoAutoNews Premium

Sun, 27 Nov 2022
VACC congratulates Andrews government - Paint and Panel

Sun, 27 Nov 2022
Richard Dudley to leave MTAA - Paint and Panel

Mon, 21 Nov 2022
2022-11-21 | NDAQ:VACC | Press Release | Vaccitech plc - Stockhouse

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 37 (M)
% Held by Insiders 1.883e+007 (%)
% Held by Institutions 31.5 (%)
Shares Short 72 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 1.097e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 29.8
Operating Margin (%) 20.1
Return on Assets (ttm) 1.8
Return on Equity (ttm) 4.6
Qtrly Rev. Growth 32
Gross Profit (p.s.) -0.28
Sales Per Share 0.01
EBITDA (p.s.) -1
Qtrly Earnings Growth 0.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 132.84
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 76330
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.